Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 25 clinical trials
Featured trial
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

metastatic cholangiocarcinoma with FGFR2 rearrangement.  

metastatic cancer
cancer
FGFR2
primary cancer
  • 207 views
  • 17 May, 2022
  • 146 locations
Biomoleculars Markers of Sensitivity to Pre- and Post-operative Chemotherapy of Gastric and Cardia Adenocarcinomas: a Pilot Study

, Her2, FGFR2) and mutations (p53 ras) in frequently deregulated genes in gastric cancers. To characterize the level of expression of predictive candidate markers (Np73, TAp73, HDAC4, mir140

  • 0 views
  • 24 Feb, 2022
  • 1 location
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (FIDES-01)

inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) whose tumors harbor FGFR2 gene fusions (by FISH performed by the central laboratory) or FGFR2 gene mutations or amplifications (based on NGS

neutrophil count
FGFR2
tubal ligation
measurable disease
icca
  • 190 views
  • 29 Jan, 2022
  • 40 locations
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Infigratinib is an oral drug which selectively binds to fibroblast growth factor receptor (FGFR) 2 and is being developed to treat participants with FGFR2 mutated cholangiocarcinoma. The purpose

  • 26 views
  • 16 May, 2022
  • 113 locations
  • 0 views
  • 25 Mar, 2022
  • 68 locations
First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

fibroblast growth factor receptor 2 (FGFR2) inhibitor administered orally patients with unresectable or metastatic ICC and other unresectable or metastatic solid tumors. This study consists of 2 parts, a

growth factor
FGFR2
antineoplastic
solid tumor
intrahepatic bile duct carcinoma
  • 5 views
  • 13 May, 2022
  • 35 locations
  • 51 views
  • 24 May, 2022
  • 160 locations
A Study of TAS-120 in Patients With Metastatic Breast Cancer

The purpose of the trial is to evaluate a patient's response to a Fibroblast Growth Factor Receptor (FGFR) inhibitor, futibatinib (TAS-120), used either alone or in combination with the hormonal therapy, fulvestrant. This study will be conducted in patients with metastatic breast cancer who have specific Fibroblast Growth Factor Receptor …

liver metastasis
endocrine therapy
platelet count
progesterone
neutrophil count
  • 76 views
  • 28 Apr, 2022
  • 28 locations
Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (FIDES-03)

adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR2 genetic aberrations (GA).

  • 0 views
  • 07 Mar, 2022
  • 79 locations
Futibatinib in Patients With Specific FGFR Aberrations

-esophageal junction (GEJ) cancer harboring FGFR2 amplification; and patients with myeloid or lymphoid neoplasms with FGFR1 rearrangements.

  • 0 views
  • 08 Dec, 2021
  • 71 locations